海吉亚医疗控股有限公司是一家主要提供医疗服务的投资控股公司。该公司通过两个业务部门开展业 务。医院业务分部从事提供肿瘤一站式综合诊疗服务，围绕肿瘤核心业务开展多学科医疗服务，包括提 供医疗放疗、化疗、手术、靶向在内的多重肿瘤医疗服务，逐步覆盖癌症诊断、治疗与康复等各阶段。 其它业务分部主要从事其他业务。该公司主要在国内市场经营其业务。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 证券之星消息，2月13日南向资金减持41.64万股海吉亚医疗（06078.HK）。近5个交易日中，获南向资 金减持的有3天，累计净减持229.5万股。近20个交易日中，获南向资金减持的有12天，累计净减持 521.74万股。截至目前，南向资金持有海吉亚医疗（06078.HK）2.0亿股，占公司已发行普通股的 32.34%。 ...

以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 海吉亚医疗控股有限公司是一家主要提供医疗服务的投资控股公司。该公司通过两个业务部门开展业 务。医院业务分部从事提供肿瘤一站式综合诊疗服务，围绕肿瘤核心业务开展多学科医疗服务，包括提 供医疗放疗、化疗、手术、靶向在内的多重肿瘤医疗服务，逐步覆盖癌症诊断、治疗与康复等各阶段。 其它业务分部主要从事其他业务。该公司主要在国内市场经营其业务。 证券之星消息，2月12日南向资金减持258.74万股海吉亚医疗（06078.HK）。近5个交易日中，获南向资 金减持的有2天，累计净减持185.7万股。近20个交易日中，获南向资金减持的有12天，累计净减持581.8 万股。截至目前，南向资金持有海吉亚医疗（06078.HK）2.01亿股，占公司已发行普通股的32.41%。 ...

Group 1 - The company, Haijia Medical (06078.HK), announced a share buyback of 140,000 shares at a total cost of HKD 1.9939 million, with a buyback price range of HKD 14.22 to 14.27 per share [1] - As of the market close on February 12, 2026, Haijia Medical's stock price was HKD 14.27, reflecting a decline of 1.11%, with a trading volume of 2.1016 million shares and a total transaction value of HKD 30.0401 million [1] - The stock is primarily rated as "Hold" by investment banks, with one bank providing a "Hold" rating in the last 90 days and a target price of HKD 13.5 [1] Group 2 - Haijia Medical has a market capitalization of HKD 8.898 billion and ranks 6th in the medical services sector [2]

Group 1 - The company, Haijia Medical (06078), announced a share buyback plan on February 12, 2026, involving an expenditure of HKD 1.9939 million to repurchase 140,000 shares at a price range of HKD 14.22 to 14.27 per share [1]

Group 1 - The company, Haijia Medical (06078.HK), announced a share buyback on February 12, 2023, spending HKD 1.994 million to repurchase 140,000 shares at a price range of HKD 14.22 to 14.27 per share [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 海吉亞醫療控股有限公司 呈交日期： 2026年2月12日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 06078 | 說明 | 普通股 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 | ...

Core Viewpoint - Southbound funds reduced their holdings in Haijia Medical (06078.HK) by 122,800 shares on February 11, while in the past five trading days, there were four days of net increases totaling 1,164,800 shares [1] Group 1: Southbound Fund Activity - In the last 20 trading days, southbound funds have reduced their holdings on 12 days, with a total net reduction of 3,828,600 shares [1] - Currently, southbound funds hold 203 million shares of Haijia Medical, accounting for 32.83% of the company's issued ordinary shares [1] Group 2: Company Overview - Haijia Medical Holdings Limited is primarily an investment holding company that provides medical services [1] - The company operates through two business segments: the hospital business segment focuses on providing comprehensive diagnosis and treatment services for tumors, including multiple cancer medical services such as radiotherapy, chemotherapy, surgery, and targeted therapy [1] - The other business segment is engaged in various other operations, with the company primarily operating in the domestic market [1]

Core Viewpoint - Hai Jiaya Medical (06078) has released its 2025 performance forecast, indicating a potential revenue decline but with signs of operational resilience and future growth opportunities [1][4]. Financial Performance - For the second half of 2025, the company expects revenue between 20.1 billion to 20.6 billion yuan, representing a year-on-year decline of 0-3% [1][4]. - Adjusted net profit is projected to be approximately 1.88 billion to 2.28 billion yuan, with a year-on-year change of -7% to +13% [1][4]. - Operating cash flow is anticipated to grow by 36% to 53% year-on-year [1][4]. Market Position and Strategy - The company's hospitals are evenly distributed across the country, which supports stable revenue growth in the second half of 2025 [1][4]. - Looking ahead to 2026, the impact of DRGs payment reform on average hospitalization costs is expected to diminish, potentially leading to positive revenue growth [1][4]. Analyst Insights - Citic Securities believes that despite the earnings warning, the decline in performance has likely reached its bottom [1][4]. - The company is expected to see a 2% year-on-year revenue decline in the second half, with adjusted net profit showing a recovery of 3% growth, indicating improving profitability resilience [1][4]. - Key growth drivers for 2026 include expanding non-national health insurance directory revenue, enhancing existing hospital utilization, and reducing debt levels to improve operational leverage and restore profit margins [1][4].

Core Viewpoint - Haijia Medical (06078) has seen a stock price increase of over 5%, currently at HKD 14.73, with a trading volume of HKD 87.87 million, following the release of its 2025 performance forecast [1] Financial Performance - For the second half of 2025, the company is expected to achieve revenue between RMB 20.1 billion and RMB 20.6 billion, representing a year-on-year decline of 0% to 3% [1] - Adjusted net profit is projected to be approximately RMB 1.88 billion to RMB 2.28 billion, reflecting a year-on-year change of -7% to +13% [1] - Operating cash flow is anticipated to grow by 36% to 53% year-on-year [1] Market Outlook - The company's hospitals are evenly distributed across the country, and revenue growth is expected to stabilize in 2025 [1] - For 2026, the impact of DRGs payment reform on average hospitalization costs is expected to diminish, potentially leading to positive revenue growth [1] Analyst Insights - Citic Securities believes that despite the earnings warning, the decline in performance has likely bottomed out [1] - The second half of 2025 is expected to see a 2% year-on-year revenue decline, with adjusted net profit anticipated to recover by 3%, indicating improving profitability resilience [1] - Key growth drivers for 2026 include expanding non-national health insurance directory revenue, enhancing existing hospital utilization rates, and reducing debt levels to improve operational leverage and restore profit margins [1]

Core Viewpoint - Southbound funds have increased their holdings in Haijia Medical (06078.HK) by 19,400 shares on February 9, indicating a positive sentiment towards the company [1] Group 1: Southbound Fund Activity - In the last 5 trading days, southbound funds have increased their holdings for 4 days, with a total net increase of 807,800 shares [1] - Over the past 20 trading days, there have been 11 days of net reductions, totaling 3,667,800 shares [1] - Currently, southbound funds hold 202 million shares of Haijia Medical, representing 32.72% of the company's issued ordinary shares [1] Group 2: Company Overview - Haijia Medical Holdings Limited is primarily an investment holding company that provides medical services [1] - The company operates through two business segments: the hospital business segment focuses on comprehensive cancer diagnosis and treatment services, including radiotherapy, chemotherapy, surgery, and targeted therapy [1] - The other business segment is involved in various other operations, with the company primarily conducting its business in the domestic market [1]